Animal studies have shown that broadly neutralizing HIV antibodies (bNAbs) can protect against infection, and are likely to be required for an effective HIV vaccine. However, despite over 20 years of research and many different immunogen designs, bNAbs have proven impossible to elicit. In contrast, many studies have confirmed that some HIV-infected individuals naturally develop bNAbs, though normally only after years of infection. Studying these natural examples of bNAbs may provide valuable insights for immunogen design. Most broadly neutralizing monoclonal antibodies (mAbs) isolated thus far have been obtained from cross- sectional screens of chronically infected individuals, which provides limited information on the ontogeny of these bNAbs. However, in the last year the developmental pathways for some bNAbs have been elucidated, by ourselves and others, in studies of longitudinal samples from infected subjects. We hypothesize that these kinds of studies are invaluable in providing an accurate roadmap from elicitation to maturation of bNAbs, with a focus on the very earliest events in their ontogeny. They enable the identification of the antibody precursors and of developmental intermediates, as well as of the viral envelope responsible for eliciting the bNAb lineage. Here, we will focus on bNAbs to the glycan-V2 and -V3 epitopes, which are the most common bNAb targets during the first years of infection. Here, we will use several parallel approaches and technologies to isolate glycan-directed bNAbs from the CAPRISA cohort of subtype C infected donors, and perform mapping and structural studies to define the antibody epitopes. As well as providing valuable tools for our proposed studies, these mAbs will help address the relative dearth of subtype C mAbs, a significant gap in the field as subtype C is the predominant global subtype. Making use of rare stored serial samples from acute infection through to the development of breadth, we will use next generation immunoglobulin gene sequencing to determine the timing of the development of antibody lineages, and to infer an unmutated common ancestor for each lineage. In parallel, viral envelope sequencing at key time points prior to and during the maturation of breadth will enable us to identify viruses that triggered these lineages, and later viral variants that shaped the maturation of breadth. Finally, we will use the knowledge gleaned regarding the ontogeny of bNAbs, to design and characterize novel structure-based immunogens based on envelopes selected specifically for their ability to bind bNAb unmutated common ancestors. In this way, we aim to harness lessons learned from infected people who naturally developed bNAbs, and apply these to the design of an HIV vaccine.

Public Health Relevance

A protective HIV vaccine will likely need to elicit broadly neutralizing antibodies. These kinds of antibodies are occasionally made by infected people such as those we propose to study. Understanding how these antibodies develop will provide a roadmap from elicitation to maturation of these antibodies, which we will harness here to design new vaccine strategies.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Singh, Anjali
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wits Health Consortium (Pty), Ltd
South Africa
Zip Code
Johnson, Erik L; Doria-Rose, Nicole A; Gorman, Jason et al. (2018) Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nat Commun 9:4136
Landais, Elise; Moore, Penny L (2018) Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Retrovirology 15:61
Moore, Penny L (2018) The Neutralizing Antibody Response to the HIV-1 Env Protein. Curr HIV Res 16:21-28
Ditse, Zanele; Muenchhoff, Maximilian; Adland, Emily et al. (2018) HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. J Virol 92:
Wibmer, Constantinos Kurt; Gorman, Jason; Ozorowski, Gabriel et al. (2017) Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog 13:e1006074
Moore, Penny L; Gorman, Jason; Doria-Rose, Nicole A et al. (2017) Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. Immunol Rev 275:217-229
Wibmer, Constantinos Kurt; Gorman, Jason; Anthony, Colin S et al. (2016) Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. J Virol 90:10220-10235
Archary, D; Seaton, K E; Passmore, J S et al. (2016) Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. Mucosal Immunol 9:821-833
Gorman, Jason; Soto, Cinque; Yang, Max M et al. (2016) Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol 23:81-90
Garrett, Nigel J; Drain, Paul K; Werner, Lise et al. (2016) Diagnostic Accuracy of the Point-of-Care Xpert HIV-1 Viral Load Assay in a South African HIV Clinic. J Acquir Immune Defic Syndr 72:e45-8

Showing the most recent 10 out of 18 publications